Atrial fibrillation (AF) is characterized by electrical, contractile, and structural remodeling mediated by interstitial fibrosis. It has been shown that human cardiac mesenchymal progenitor cells (CMPCs) can be differentiated into endothelial, smooth muscle, and fibroblast cells. Here, we have investigated, for the first time, the contribution of CMPCs in the fibrotic process occurring in AF. As expected, right auricolae samples displayed significantly higher fibrosis in AF vs control (CTR) patients. In tissue samples of AF patients only, double staining for c-kit and the myofibroblast marker α-smooth muscle actin (α-SMA) was detected. The number of c-kit-positive CMPC was higher in atrial subepicardial regions of CTR than AF cells. AF-derived CMPC (AF-CMPC) and CTR-derived CMPC (Ctr-CMPC) were phenotypically similar, except for CD90 and c-kit, which were significantly more present in AF and CTR cells, respectively. Moreover, AF showed a lower rate of population doubling and fold enrichment vs Ctr-CMPC. When exogenously challenged with the profibrotic transforming growth factor-β1 (TGF-β1), AF-CMPC showed a significantly higher nuclear translocation of SMAD2 than Ctr-CMPC. In addition, TGF-β1 treatment induced the upregulation of COL1A1 and COL1A2 in AF-CMPC only. Further, both a marked production of soluble collagen and α-SMA upregulation have been observed in AF-CMPC only. Finally, electrophysiological studies showed that the inwardly rectifying potassium current (I K1) was evenly present in AF-and Ctr-CMPC in basal conditions and similarly disappeared after TGF-β1 exposure. All together, these data suggest that AF steers the resident atrial CMPC compartment toward an electrically inert profibrotic phenotype. (Translational Research 2018;192:54-67) Abbreviations: AF = atrial fibrillation; TGF-β1 = transforming growth factor-β1; CMPC = cardiac mesenchymal progenitor cell; MFB = myofibroblast; α-SMA = α-smooth muscle actin; ECM = extracellular matrix; CTR = controls in sinus rhythm; BMI = body mass index; α-SA = α-sarcomeric actin; HLA = human leucocyte antigen; FACS = Fluorescence-activated cell sorting; CPD = cumulative population doubling; NCX1 = sodium-calcium exchanger
INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting millions of people worldwide with high mortality and morbidity rates. 1 AF is characterized by a high rate of asynchronous atrial cell depolarization, causing a loss of atrial contractile function and irregular ventricular rates. 2 It has been unambiguously reported that atrial fibrosis plays a central role in AF pathogenesis. 3 In this context, transforming growth factor-β1 (TGF-β1) is pivotal in the fibrotic process, both in animal models and in humans, by stimulating myofibroblast (MFB) differentiation and collagen production through the SMAD signaling pathway. 4 Moreover, it has been shown that TGF-β1 expression proportionally increases with the degree of atrial fibrosis in AF. 5 Collagen deposition around cardiomyocytes (interstitial atrial fibrosis) may be the result of nonspecific scar-like reparative mechanisms following cardiomyocyte necrosis, being the most threatening change in the setting of atrial structural remodeling in AF. 6 Atrial fibrosis is characterized by the appearance of interstitial MFB. These cells are responsible for the deposition of the extracellular matrix (ECM) that causes cardiomyocyte disarray.
Although major progress has been made in pharmacologic and interventional treatments, persistence and recurrence remain critical problems for patients with AF. To date, the exact pathogenic mechanism responsible for AF is still unclear. An improved understanding of the pathophysiology underlying fibrotic atrial remodeling may be relevant for the development of novel therapeutic approaches.
We and others have reported the presence of a resident population of human c-kit + cardiac mesenchymal progenitor cells (CMPCs) [7] [8] [9] [10] that can be differentiated into endothelial, smooth muscle, and, to a lesser extent, fibroblasts. 7, 8, 10, 11 Although the concept that CMPCs are cardiomyocyte precursors in the adult heart has been questioned, 12 there is enough evidence that this cell population plays anyhow a role in cardiac tissue homeostasis. 13, 14 Notably, in vitro and in vivo findings suggest that either an impairment or an alteration of the CMPC compartment is associated with the initiation and progression of different cardiac conditions. [15] [16] [17] [18] Nevertheless, the role and contribution of CMPC in AF pathogenesis, with particular regard to fibrosis and electric dysfunction, is still poorly understood. We have previously shown that AF impairs CMPC amplification potential ex vivo. 19 Accordingly, adjunctive evidence has been recently provided that CMPC number is reduced in patients with AF, suggesting impairments in selfrenewal capability. 20 In the present work, we have investigated the MFB differentiation of human CMPC vs controls in sinus rhythm (CTR) obtained from atrial specimens of patients undergoing cardiac surgery. The hypothesis of this study is whether AF is associated, in vitro and ex vivo, with a preferential profibrotic shift in the differentiation program of CMPC.
MATERIALS AND METHODS
Patients and tissue samples. Specimens from right atrial appendages were obtained between May 2012 and January 2014 from 22 Caucasian patients undergoing elective valve surgery. Signed informed consent previously approved by the local ethics committee (R198-CCFM S202/312) was obtained for each patient in accordance with the Declaration of Helsinki. Each tissue sample was divided into 2 parts for CMPC in vitro experiments and tissue analyses, respectively. Patients enrolled in this study were allocated into 2 groups: persistent AF and CTR. In addition to the complete medical record, the following relevant information were obtained for each patient on admission to the hospital: age, gender, body mass index, cardiovascular risk factors, drug therapy, and echocardiographic data. Patients were excluded if any of the following criteria were met: (1) presence of coronary artery disease; (2) age >80 years; (3) positivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, Treponema pallidum (VDRL); or (4) cardiac surgery in emergency department.
AT A GLANCE COMMENTARY
Gambini E, et al.
Background
Atrial fibrillation (AF) is characterized by electrical, contractile, and structural remodeling, mediated by interstitial fibrosis. It is known that human cardiac mesenchymal progenitor cells (CMPCs) can differentiate into cardiomyocyte, fibroblast, endothelial, and smooth muscle cells. In vitro and in vivo findings suggest that either an impairment or an alteration of the CMPC compartment is associated with the initiation and progression of cardiomyopathies. The role of CMPC in AF pathogenesis is still unknown.
Translational Significance
Understanding how CMPCs are involved in the development of atrial interstitial fibrosis in AF could be important for future investigations on biological therapies influencing AF.
CMPC isolation and culture. The procedure to obtain and expand CMPC from right atrial appendages was carried out as previously reported. 7 Briefly, the myocardial tissue was digested 4 times at 37°C in a 3 mg/mL collagenase solution (Serva) and cultured in Ham's F12 medium (Lonza) with 10% fetal bovine serum (FBS; Thermo Fisher Scientific), 2 mM l-glutathione, and 5 × 10 −3 U/mL human erythropoietin (Sigma-Aldrich), 10 ng/mL basic fibroblast growth factor (Peprotech), and antibiotics (Lonza). After a pre-expansion period, cells were stained with allophycocyanin (APC)-conjugated monoclonal antibodies directed against human c-kit receptor (anti-CD117, clone YB5.B8; BD Biosciences), analyzed, and sorted by flow cytometry (FACSAria, BD Biosciences). Sorting setup and appropriate gating were established using cells labeled with APC-conjugated isotype control antibody at the same concentration. An appropriate gating strategy has been adopted to selected cells expressing c-kit at high levels only. CMPCs were treated with TGF-β1 (2 ng/mL) from 3 hours to 10 days to assess differentiation toward MFB cell type. TGF-β1 was added every 48 hours. In particular, we treated CMPC for (1) 10 minutes to assess phosphorylation of SMAD2; (2) 3 hours to assess SMAD2 nuclear translocation; (3) 48 hours to analyze collagen gene expression by real-time polymerase chain reaction (PCR); (4) 5 days to study the in vitro collagen deposition; and (5) 10 days to demonstrate in vitro myofibroblast differentiation using α-smooth muscle actin (α-SMA) immunofluorescence. Following laboratory best practices, the lower cell sample has been used when a high significant difference between groups has been reached.
Immunofluorescence and confocal analysis. Fragments from atrial appendages were fixed in paraformaldehyde and embedded in paraffin. Sections were deparaffinized, rehydrated, boiled in antigen retrieval buffer with sodium citrate, and incubated with primary antibody at 4°C overnight (O/N): c-kit-biotin (LifeSpan BioSciences, Inc.), α-sarcomeric actin (α-SA; Sigma-Aldrich), collagen type I (Coll I; Abcam), α-SMA (Merck Millipore). After washing, sections were incubated with the following fluorochrome-conjugated antibodies for 1 hour at room temperature in the dark: Streptavidin 488 (Life Technologies), DyLight 549 (Jackson ImmunoResearch), Alexa 488 (Life Technologies), and Alexa 594 (Life Technologies). Nuclei were stained with Hoechst 33342 (Sigma-Aldrich). Fibrosis was determined by a densitometric analysis of sections stained with a specific antibody detecting collagen type I and the specific cardiomyocyte marker α-SA. The ratio between the number of collagen type I pixels (Coll I area sum) and the number of α-SA pixels (α-SA area sum) were calculated with the AxioVision software (Carl Zeiss). In other sections, CMPC niches were identified by an anti-c-kit biotin antibody and by counting c-kit + cells in 10 random fields. Immunofluorescence was performed at T0 on CMPC untreated or treated with TGF-β1 (2 ng/mL), seeded on chamber slides. After washing, CMPCs were incubated O/N in the dark, at 4°C with the following antibodies: α-SMA (Merck Millipore) and CD90 (Abcam). The day after, cells were incubated with the following fluorochrome-conjugated antibodies for 1 hour at room temperature in the dark: Alexa 488 and Alexa 633 (both from Life Technologies). Nuclei were stained with Hoechst 33342 (SigmaAldrich). Analysis was performed using a Zeiss LSM 710 confocal microscope. The number of CMPC was normalized to the section area calculated with ZEN 2008 software (Carl Zeiss).
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Flow cytometry. Immunophenotype analysis of mesenchymal, endothelial, human leucocyte antigen (HLA), and hematopoietic markers was performed by multicolor flow cytometry on c-kit + -derived cells. After detachment using a nonenzymatic method, cells were resuspended in phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA; Gibco) and 2 mM ethylenediaminetetraacetic acid (EDTA; Gibco) and incubated in the dark for 15 minutes with suitable combinations of the monoclonal antibodies (Supplementary  Table S1 ) or isotype-matched control monoclonal antibodies: c-kit-APC (clone YB5.B8), CD34-FITC (clone 581), CD45-PE (clone HI30), CD29-PE (clone MAR4), CD31-FITC (clone WM59), CD90-FITC (clone 5E10), CD130-PE (clone AM64), HLA-DR-FITC (clone G46-6), CD73-PE (clone AD2) (BD Pharmingen), CD146-FITC (clone 128018), CD200-FITC (clone 325516), KDR-PE (clone 89106) (R&D Systems), Lineage-biotin (Miltenyi Biotec), HLA-G-PE (clone MEM-G/9) (Exbio Praha), and CD144-Alexa700 (clone 16B1; eBioscience). Samples were then washed with 1 mL of washing buffer and centrifuged for 10 minutes at 400 × g at 4°C to remove unbound antibodies. Cells were resuspended in 250 µL of washing buffer and analyzed.
Cumulative population doublings and fold enrichment.
Population doubling (PD) levels of CMPC were calculated at every passage in culture using the following equation: PD=Log N/Log 2, where N is the number of cells harvested at the end of the culture or number of seeded cells. Cumulative PD was calculated by adding the PD of the passage under analysis to the PD of the previous passages. The CMPC fold enrichment in culture was calculated as the ratio of the number of c-kit + cells at passage 3 (P3)/number of sorted c-kit + cells at T0.
ImageStreamX assay. Nuclear translocation of SMAD2 in CMPC after TGF-β1 treatment was evaluated by ImageStream X flow cytometer, which combines flow cytometry with confocal microscopy technology (ImageStream X Mark II, Amnis). CMPC from CTR patients (Ctr-CMPC) and CMPC from patients with AF (AF-CMPC) were cultured in Ham's F12 medium supplemented with 10% FBS and treated with 2 ng/mL TGF-β1 (Peprotech) for 3 hours. After detachment from Petri dishes using a nonenzymatic method, cells were resuspended in 100 µL of PBS containing 0.1% BSA (Gibco) and 2 mM EDTA (Gibco) and incubated in the dark for 15 minutes with 0.5 µg/mL anti-SMAD2 primary antibody conjuagated with fluorescein isothiocyanate (FITC) (Abcam). Samples were then washed with 1 mL per tube of washing buffer and centrifuged for 10 minutes at 400 × g at 4°C to remove unbound antibodies. Cells were resuspended in 100 µL of PBS containing 0.1% BSA and 2 mM EDTA, incubated with 2.5 µM nuclei fluorescent staining DRAQ5 (Abcam), and analyzed. Instrument and INSPIRE software were set up as follows: Ch01 for bright-field, Ch02 for FITC fluorescence intensity, Ch05 for APC fluorescence intensity, and Ch06 for side-scatter intensity. All samples were acquired with 40× magnification at a low flow rate or high sensitivity, and 488, 630, and 785 lasers were activated for FITC fluorescence, APC fluorescence, and side-scatter intensity, respectively. CMPCs were gated on a dot plot reporting area ("x" axis) and aspect ratio ("y" axis) to eliminate clumps. A total of 10,000 events in the CMPC gated area were acquired. Image analysis was performed using the IDEAS image analysis software. The degree of fluorescence relative to SMAD2-FITC staining was quantified using the Intensity_MC_Ch02, whereas DRAQ5 staining was quantified using the Intensity_MC_Ch05. To evaluate FITC-APC overlapping signal, a Similarity Dilate analysis on Intensity_MC_Ch02 and Intensity_MC_Ch05 was performed.
Western blot analysis. CMPCs were lysed in cell lysis buffer (Cell Signaling Technology) supplemented with protease and phosphatase inhibitor cocktails (Sigma Aldrich). Total cell proteins were subjected to sodiumdodecyl-sulfate polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. The membranes were blocked for 1 hour at room temperature in 5% non-fat dry milk in wash buffer (0.1% Tween 20 in Tris buffered saline, T-TBS) and then incubated O/N at 4°C with the appropriate primary antibody. The primary antibodies used were specific for phospho-SMAD2/3 (Cell Signaling Technology), total SMAD2/3 (Cell Signaling Technology), α-SMA (Merck Millipore), CD90 (Abcam), Nkx2.5 (Santa Cruz Biotechnology), GATA-4 (Santa Cruz Biotechnology), and GAPDH (Santa Cruz Biotechnology). The membranes were incubated with peroxidaseconjugated secondary antibodies for 1 hour. Signals were visualized using enhanced chemiluminescence Western blotting detection system (Thermo Fisher Scientific). Images were acquired with the Alliance Mini 2M (UVITEC Cambridge), and densitometric analysis of membranes was performed using the Alliance Mini 4 16.07 software (UVITEC Cambridge).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). At P3, before, and after culturing in differentiation media (EpiC for cardiac or TGF-β1 for MFB differentiation), total RNA was purified from CMPC using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed (RT) using SuperScriptIII cDNA synthesis kit (Invitrogen). Synthesized cDNA was treated with 2 U RNAse H at 37°C for 30 minutes. After reverse transcription, specific primers for early and late cardiac genes, ion channel genes, and collagen genes were used to assess the cell phenotype. Real-time qRT-PCR analysis was performed using iQ5 Real-Time PCR System (Bio-Rad). Each primer pair, designed from available human sequences using the software Primer Express v3.0 (Applied Biosystems), was tested in triplicate using 10 ng of cDNA. The PCR included 10 ng of template cDNA, 0.2 µM each (forward and reverse) primer, 3.5 µL of RNAse-free water, and 7.5 µL of iQ SYBR Green Supermix conjugated with the fluorescent dye FAM (Bio-Rad) in a total volume of 15 µL. Cycling conditions were as follows: 95°C for 10 minutes, followed by 40 amplification cycles of 15 minutes at 95°C for denaturation, and 1 minute at 60°C for annealing or elongation. Melting curves were acquired after PCR to confirm the specificity of the amplified products. Quantified values were normalized against the input determined by the housekeeping gene human β-2-microglobulin. Data were expressed and plotted as fold change calculated by normalizing the relative expression (calculated by the 2-ΔΔCt method) to reference cells. In particular, each gene ΔΔCt was calculated on the mean of the ΔCt of the control group (T0). The qRT-PCR graphs show the mean of the differences between the threshold cycle (CT) for each amplified transcript and the housekeeping gene (ΔCT), expressed as [(CT target gene) − (CT housekeeping gene)]. Primer pairs used are indicated in Supplementary Table S2 .
Sircol assay. Total soluble collagen content in cell lysates and supernatant from Ctr-CMPC and AF-CMPC, treated with TGF-β1 for 5 days, was measured using Sircol soluble collagen assays (Biocolor) as described in the manufacturer's protocol. The quantity of collagen was calculated according to a standard curve.
Electrophysiology. Voltage-clamp analyses were performed at 3 days after cell sorting (T0) and 10 days after TGF-β1 treatment (TGF-β1). For T0 analysis, cells were plated at low density. For the other time points, cells were detached by TrypLE (Life Technologies) and plated at a low density the day before the analysis. Cells were placed onto the stage of an inverted microscope and perfused with the Tyrode solution containing: 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5.5 mM d-glucose, 5 mM HEPES-NaOH pH 7.4. Patch-clamp pipettes were filled with an intracellular-like solution containing 130 mM K-aspartate, 10 mM NaCl, 5 mM EGTA-KOH, 2 mM CaCl2, 2 mM MgCl2, 2 mM ATP (Nasalt), 5 mM phosphocreatine, 0.1 mM GTP (Na-salt), 10 mM HEPES-KOH pH 7.2. Cells were kept at room temperature. The inward-rectifier potassium current (IK1) was recorded from single cells in whole-cell configuration as the Ba Statistical analysis. Quantitative results are expressed as mean ± standard deviation or standard error (SE). Variables were analyzed by Student t test. Statistical significance was evaluated with GraphPad Prism 5, and a value of P ≤ 0.05 was considered as statistically significant.
RESULTS
Patient characteristics. Details of patient characteristics are shown in Table I . A total of 22 cardiac specimens (right atrial appendages) from patients undergoing isolated aortic (n = 13), or combined mitral-tricuspid (n = 6), aortic-tricuspid (n = 1), or aortic-mitral-tricuspid (n = 2) valve surgery, showing permanent AF (AF group; n = 11) or sinus rhythm (CTR group; n = 11) were analyzed. The 2 groups were matched for age and gender. Cardiovascular risk factors and medication profile were also similar in both groups. No patient reported alcohol abuse in both groups. The mean AF duration was 7.8 ± 2.7 years (mean ± SE). As expected, the vast majority of patients with AF underwent mitral and tricuspid valve surgery (P < 0.01), whereas CTR patients underwent aortic valve surgery (P < 0.01). In addition, at preoperative transthoracic echocardiography, patients with AF showed a significantly greater left atrial dimension, expressed as area (cm 2 ), compared with CTR patients (P < 0.05). Tissue characterization and CMPC localization. Increased collagen deposition has been well documented in patients with AF compared with CTR subjects. 21 Using a densitometric analysis, we found that right auricolae fragments recapitulated left atrial fibrotic remodeling in patients with AF (Fig 1, A-C) , showing significantly higher fibrosis vs CTR patients (P < 0.001, n = 3). By immunofluorescence analysis, the presence of isolated or clustered c-kit + cells in subepicardial or subendocardial zones has been detected (Fig 1, D-H) . Of note, CMPC number was found to be significantly higher in the subepicardial region of CTR than in patients withAF (P < 0.05, ). *Pulmonary hypertension was defined as systolic pulmonary artery pressure ≥40 mm Hg. n = 3) and not different in the subendocardial territory. To preliminary test at tissue level a possible involvement of CMPC as cellular origin of MFB, we checked for c-kit + cells co-expressing α-SMA in AF and CTR tissue samples. Of interest, in CTR section c-kit + cells did not express α-SMA, which specifically identifies smooth muscle cells of vessels (Fig 1, I) ; otherwise, doublepositive c-kit
+ cells have been observed in AF section only (Fig 1, J) in nonperivascular regions.
CMPC isolation and amplification. Cardiac tissue samples were processed for CMPC isolation (purity > 80%) and in vitro assays. AF-CMPC were characterized by a lower rate of PD (P < 0.05, n = 7) and fold enrichment (P < 0.05, n = 5) compared with Ctr-CMPC (Fig 2, A and B) , in agreement with our previously reported data.
19 fluorescence-activated cell sorting (FACS) analysis revealed that AF-CMPC and Ctr-CMPC showed a similar percentage of positivity for surface antigens Representative images of human right atrial appendage section from CTR (I) and AF (J) patients immunostained with c-kit (green), α-SMA (red) antibodies, and Hoechst 33258 for nuclei (blue), *P < 0.05, ***P < 0.001. All data were representative of 3 independent experiments. AF, atrial fibrillation; α-SMA, α-smooth muscle actin; α-SA, α-sarcomeric actin; CMPC, cardiac mesenchymal progenitor cell; CTR, control. Table S1 and Fig S1) ; however, c-kit (CD117) was higher in Ctr-CMPC compared with AF-CMPC (Fig 2, C) , whereas CD90 was higher in AF-CMPC compared with Ctr-CMPC (Fig 2, D) (P < 0.05, n = 6).
typical of mesenchymal cells (Supplementary
In vitro effects of TGF-β1 treatment on CMPC. To study whether a fibrotic process may be triggered in the CMPC population, AF-and Ctr-CMPC have been exposed to TGF-β1 to evaluate the nuclear translocation of SMAD2, a downstream transcription factor involved in the TGF-β1 pathway. Although TGF-β1 treatment induced the nuclear translocation of SMAD2 in both cell types, the differences between nuclear localization of SMAD2 before and after TGF-β1 treatment (Δ similarity dilate cell percentage) was significantly higher in AF-CMPC than in Ctr-CMPC (11.08 ± 0.38 vs 17.68 ± 0.33, P < 0.001) (Fig 3, A and B) . These results were further confirmed by Western blot assay on CMPC exposed to TGF-β1. The expression level of active SMAD2 (phospho-SMAD2) was significantly higher in AF-CMPC after TGF-β1 treatment in comparison with both untreated AF-CMPC (P < 0.01) and treated Ctr-CMPC (P < 0.05) (Fig 3, C) . Although it has already been shown that TGF-β1 activates phospho-SMAD2 translocation into the nucleus thus activating its downstream pathway, we demonstrated for the first time such an overactivation in human CMPC and a preferential activation in AF-CMPC.
Further, to analyze the differentiation ability of CMPC into MFB, we took advantage of different assays at various time points to follow such progression. Specifically, (1) after 48 hours of TGF-β1 treatment, we showed the upregulation of COL1A1 (P < 0.05) and COL1A2 (P < 0.05) genes in AF-CMPC only; on the contrary, COL3A1 gene expression was upregulated both in Ctrand in AF-CMPC after treatment, and also in treated Ctr-CMPC vs treated AF-CMPC (P < 0.05) (Fig 3, D) ; (2) after 5 days of TGF-β1 treatment, we found a significant production of soluble collagen, as detected by Sircol assay, in AF-CMPC only (5.64 ± 1.58 µg/mL in AF-CMPC vs 2.34 ± 0.54 µg/mL in Ctr-CMPC, P < 0.05; n = 4), (Fig 4, A) ; (3) as a confirmation of the CMPC differentiation into MFB and as further evidence of SMAD2 activation, a significant α-SMA upregulation associated with a downregulation of CD90 was observed in AF-CMPC by immunofluorescence as well as by Western blot analyses after 10 days of TGF-β1 treatment (Fig 4, B-D) .
CMPC early cardiogenic commitment and ion channels gene expression after TGF-β1 treatment. To evaluate the early CMPC cardiogenic commitment, qRT-PCR for early cardiac markers was performed at T0 and after 10 days of TGF-β1 exposure in both groups. Interestingly, we observed at baseline a significant higher expression of early cardiac genes (GATA-4, Nkx2.5, and HAND-2) in AF-CMPC than in Ctr-CMPC (P < 0.05) followed by a significant decrease after TGF-β1 exposure in AF-CMPC only (Supplementary Fig S2, A) . The gene expression profiles of Nkx2.5 and GATA-4 were found to be paralleled at a protein level by Western blot analysis ( Supplementary Fig S2, B) .
We also checked the expression of different ion channel genes (Supplementary Table S2 ) at T0 and after 10 days of TGF-β1 treatment. We detected no variation in the genes analyzed between Ctr-and AF-CMPC with the exception of NCX1, which was significantly downregulated in both groups after TGF-β1 treatment, and of CACNA1C and Kv4.3, which were significantly upregulated in Ctr-CMPC only after TGF-β1 treatment ( Supplementary Fig S2, A) . Notably, Kir2.1 gene expression was significantly downregulated in both groups after TGF-β1 treatment (Fig 5, A) .
CMPC electrophysiological studies. Given the previously reported implication of potassium channel variations with collagen deposition in fibroblasts, 22 we performed electrophysiological studies in AF and Ctr-CMPC before (T0) and after TGF-β1 treatment to study the IK1 current. The cell capacitance was significantly higher in both groups after TGF-β1 treatment, and Ctr-CMPC showed higher cell capacitance vs AF-CMPC in basal conditions and after TGF-β1 treatment (Fig 5, B) . In agreement with Kir2.1 gene expression data, shown in Fig 5, A, both Ctr-and AF-CMPC at T0 similarly expressed a Ba 2+ -sensitive IK1 current (Ctr-CMPC −2.2 ± 0.4 pA/ pF, n = 6 AF-CMPC −2.3 ± 0.5 pA/pF, n = 8 at −100 mV), which almost disappeared after TGF-β1 treatment (Ctr-CMPC −0.17 ± 0.22 pA/pF, n = 8; AF-CMPC −0.26 ± 0.67 pA/pF, n = 6 at −100 mV) (Fig 5, C and D) . Because mRNA of both HCN4 and the sodium channel Nav1.5 are expressed in Ctr-and AF-CMPC at basal level, we have also evaluated at the same time point the If (carried by HCN4) and INa (carried by Nav1.5) currents. We never recorded If in both cell groups; INa was recorded in 1 Ctr-and 1 AF-CMPC out of 19 and 21 cells analyzed, respectively (data not shown).
DISCUSSION
In this study, we reported for the first time that the differentiation program of cardiac mesenchymal c-kit + atrial cells undergoes a profibrotic shift in the presence of AF. Specifically, we showed that resident CMPCs taken from the right atrial appendages of patients with AF are fewer and show a diminished expansion capability with respect to those isolated from CTR patients. More importantly, AF-derived CMPC can differentiate at both tissue level and in vitro into MFB, triggering reactive collagen deposition. Finally, we found that AF-CMPCs do not show , and GAPDH on Ctr-and AF-CMPC treated with TGF-β1 for 10 days. Quantification reported the ratio between α-SMA and CD90 signals. **P < 0.01, ***P < 0.001. (C) Representative images of immunofluorescence on Ctr-and AF-CMPC for CD90 (green) and α-SMA (red) after 10 days of treatment with TGF-β1. Nuclei are stained with Hoechst 33258 (blue). (D) Densitometric analysis of the ratio between α-SMA and CD90 fluorescence intensity. Data showed the average of 3 images. *P < 0.05, n = 3. AF-CMPC, AF-derived cardiac mesenchymal progenitor cell; Ctr-CMPC, CTR-derived cardiac mesenchymal progenitor cell; TGF-β1, transforming growth factor-β1. differences vs Ctr-CMPC in k(+)-dependent channel genes and relative functional patterns.
Recently, Shinohara et al 20 have reported that the ratio of c-kit + cells contained in outgrowth cells from left atrial tissue did not increase in the presence of AF and that the number of total cells, including c-kit + cells, were decreased in AF group vs CTR group after in vitro expansion. The authors inferred from these results that the impairment in self-renewal of these cells might concur with a diminished healing capability of AF atrial tissue upon remodeling injury. Our results confirmed that CMPCs are significantly less abundant in atrial tissue of AF compared with CTR patients, being such a reduction observed in the subepicardial region only, whereas no differences were detected at the endocardial level. These findings are in agreement with previously reported data on the relatively small contribution of endocardial cells to the adult heart interstitial fibroblast compartment. 23 Moreover, we found that AF-CMPCs are characterized in culture by a lower rate of fold enrichment compared with Ctr-CMPC, as well as by an impairment of the CPD. This evidence parallels our previous finding of a robust negative association between AF and in vitro CMPC proliferation 19 and concurs with Shinohara et al's 20 findings. Whether such a proliferation impairment is due to a cell exhaustion process or to an enhanced differentiation commitment, this is at present a matter of mere speculation and deserves further investigation.
To date, anyhow, no adjunctive information is available in the literature about the relative contribution of the CMPC compartment to develop atrial structural damage in AF. The critical association between AF, reactive interstitial fibrosis, and ECM deposition leading to atrial remodeling is well established. 24 Fibrosis is now viewed as the disease process that triggers the initiation and maintenance of AF 25 and the occurrence of supraventricular arrhythmias through local reentry circuits. Increased collagen deposition is present in patients with AF secondary to mitral valve disease vs those in sinus rhythm 26 because ECM volume and composition are in direct correlation with AF persistence. 27 Notably, although these findings highlight the association between atrial fibrosis and AF, the demonstration of a causal relationship of ECM deposition in AF occurrence and persistence remains an important challenge. 28 Mechanistically, converging data implicate the crucial role of TGF-β1 as a profibrotic molecule involved in the remodeling of atrial fibrotic structure. 29 The principal cellular effectors of reactive interstitial fibrosis are MFBs, which appear in the myocardium following pathological conditions. The most reliable marker for MFB is α-SMA, which is expressed in smooth muscle cells but not in fibroblasts. MFBs are the main producers of ECM, critically contributing to reactive cardiac fibrosis, 30, 31 being TGF-β1 the main molecular driver of their role in fibrotic process. [32] [33] [34] Although MFBs are generally believed to be derived through the activation of resident cardiac fibroblasts, this view has been challenged by the demonstration of phenotypic heterogeneity among mesenchymal-derived fibroblast populations, 23, 35 not only between organs, but also within the same organ during health and disease. 36, 37 Although the cardiomyogenic potential of c-kit + CMPC in adulthood has been questioned, 12 there is enough evidence so far indicating that resident c-kit + CMPCs present in the adult heart possess a mesenchymal phenotype and are capable of contributing significantly to nonmyocardial lineages (fibroblasts, smooth muscle cells, and endothelial cells). 11, 38, 39 Consistently, we characterized resident c-kit + CMPC as a cell population expressing typical mesenchymal markers. 7 Moreover, CMPCs have been described to play a role in physiologic cardiac homeostasis and in the pathogenesis of various cardiac conditions, including myocardial infarction and cardiomyopathies. 15, [40] [41] [42] [43] Of interest, in this work, we initially observed at heart tissue level the presence of c-kit + cells co-expressing the typical MFB marker α-SMA in AF but not in CTR samples. We then speculated that AF atrial substrate remodeling may directly influence CMPC differentiation fate.
We subsequently showed, for the first time, that the presence of AF impairs atrial CMPC amplification potential ex vivo. 19 As an additional finding, this study suggests that, when appropriately stimulated, AFCMPCs are shifted toward a preferential MFB differentiation compared with Ctr-CMPC. Specifically, after TGF-β1 treatment, AF-CMPC showed with respect to Ctr-CMPC: (1) an increased SMAD2 phosphorylation and subsequent nuclear translocation, which is known to regulate, through the TGF-β1 pathway, 44 the transcription of profibrotic target genes; (2) an increased in vitro expression of the specific MFB marker α-SMA, together with a substantial loss of CD90; and (3) an increased capacity of collagen production. In particular, collagen upregulation in TGF-β1-treated AF-CMPC has been confirmed in our experiments at both transcript and protein levels. Major components of ECM are collagen type I, which is produced by cardiac fibroblasts and accounts for about 80% of collagen in the whole heart tissue, and type III, which is preferentially found in the myocardium. 45, 46 The most detrimental event in the interstitial fibrotic process is the deposition of the thicker type I collagen, which confers an increased stiffness to the cardiac tissue 47 and is involved in different pathological conditions, 48 including AF. Of note, upon TGF-β1 stimulation, both transcripts of the 2 main collagen I isoforms were found to be more significantly increased in AF vs Ctr-CMPC. As further evidence, the well-known mesenchymal surface marker CD90 was the only among many we identified to be significantly more expressed in AF-than Ctr-CMPC, as shown in Fig 2, D  and Fig 4, B and C. Because, as previously described, 49 CD90 has been used as positive control for fibroblasts in various organs, such a distinct distribution of the Thy-1 protein observed in our AF-vs Ctr-CMPC populations provides an additional confirmation of a shift of the differentiation program of AF-CMPC into MFB. Of note, these findings are in agreement with the previously reported typical hallmarks of MFB, which show low rate of fold enrichment and concomitant α-SMA expression. 50 A proposed mechanistic elucidation of CMPC differentiation into MFB in AF scenario has been summarized in Fig 6. Intriguingly, a broad basal difference between AF and CTR was revealed in the expression of a core cardiac transcriptional network, with particular regard to 4 genes distinctive of early cardiac commitment (Nkx2.5, Gata-4, and Hand-2). The potential early cardiac plasticity of cardiac mesenchymal-derived cells is not surprising. Furtado et al 23 reported that a plethora of early cardiac genes were all significantly upregulated in subpopulations of cardiac fibroblasts compared with tail fibroblasts. Moreover, there is robust evidence that c-kit + cardiac progenitors may show early cardiomyocyte markers. 13 Interestingly, our unprecedented findings indicate that the primary AF-CMPC population is more primed for myogenic transdifferentiation at the basal level compared with Ctr-CMPC, and that this difference is suppressed by TGF-β1 stimulation. Although we do not have a clear explanation for these data, one can speculate that an initial cardiogenic response of CMPC to atrial tissue damage occurring in AF cannot be sustained once the fibrotic stimulus is established.
Besides the concept that reactive interstitial fibrosis contributes to cardiac arrhythmias by affecting passive properties of impulse conduction, recent studies demonstrated that fibroblasts and MFB may play an active arrhythmogenic role in AF driving inward current for cardiac impulse conduction, and therefore generating an arrhythmogenic uniformly slow propagation. 28 Cardiac fibroblasts are well known to possess a range of ion channels, although their functional roles are still poorly characterized. It has been recently demonstrated that the upregulation of the background IK1 current in atrial fibroblasts from chronic heart failure hearts may play a role in promoting fibroblast remodeling and structural or arrhythmic alterations. 51 Moreover, Zhang et al 52 have recently reported the existence of several ionic currents in human cardiac c-kit + progenitors such as the inwardly rectifying K + current, present in 84% of cells. We then sought to investigate the ion channels and arrhythmic profile of AF-vs Ctr-CMPC in both basal and TGF-β1 stimulated conditions. Of interest, no basal differences were found as for multiple ion channel genes in AF vs CTR. In both cell types, TGF-β1 exposure led to a significant downregulation of the NCX1 and, of the Kir2.1 inward-rectifier potassium ion channel. Notably, patchclamp recording showed a suppression of the I k1 current upon TGF-β1 stimulation in both Ctr-and AF-CMPC. These findings may have implications as for CMPC profile in AF. First, AF-CMPC Kv-channel gene downregulation may play a profibrotic role in AF substrate, as previously demonstrated in canine atrial fibroblasts. 22 Second, the lack of difference between Ctr-and AF-CMPC in k(+)-dependent channel genes and relative functional patterns at both basal and profibrotic conditions suggests that CMPC may not play an active role in AF electric atrial remodeling.
All together, we believe these data are supportive for a contributive role of the CMPC population to the development of atrial interstitial fibrosis in AF. Although resident CMPCs have reported in this study and by others to be scarcely represented within the whole mesenchymal stromal compartment, 53 their involvement in collagen deposition may be nevertheless not negligible and remains to be clarified.
Limitations. We acknowledge that study specimens have been obtained from the right atrium only. However, the concordance of published in vitro data reported with CMPC from left atrial appendages 20 is reassuring as to the reliability of our results. Second, we are well aware that, as previously mentioned, 39 it is theoretically possible that in vitro conditions may increase or shift the differentiation capacity of CMPC from certain lineages to others, whereas in the in vivo setting environmental signals may limit this phenomenon, even in response to injury. However, we believe that the multiple pieces of evidence we have collected in this work, including in vivo data, are convincing as for a preferential profibrotic shift of AF-CMPC vs controls. Finally, we do not have an explanation for differences observed in cell capacitance of AF-CMPC vs Ctr-CMPC.
Conclusion. Cumulatively, our data suggest that resident CMPCs are impacted in number and function by AF, which steers their differentiation capability toward a myofibroblast profibrotic phenotype. On the contrary, no evidence has been collected as to the differences between AF-and Ctr-CMPC in the electrophysiological profile. the journal's policy on conflicts of interest. The authors declare no competing financial interests. We are thankful to Aoife Gowran, PhD, for revising the manuscript.
